Genetic Alterations and clinical record in radically resected colorectal cancer revealed by Liquid biopsy And whole eXome analYsis - GALAXY trial

ational Research and Development Agency, National Cancer Center0 sites6,300 target enrollmentJanuary 20, 2020

ConditionsColon and Rectal cancer that can be treated radically

Overview

Phase: 未知
Intervention: Not specified
Conditions: Colon and Rectal cancer that can be treated radically
Sponsor: ational Research and Development Agency, National Cancer Center
Enrollment: 6300
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

January 20, 2020

End Date

March 31, 2031

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

ational Research and Development Agency, National Cancer Center

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•(1\) Two or more synchronous colorectal cancer (multiple cancer) \* \* In case of patients with stage II, III, IV or recurrent (M1\) colorectal cancer according to the 8th edition of the UICC, patients with clinical stage Tis or T1a colorectal cancer judged to be cured by local treatment may be included in this study. \* If patients with pT1 colorectal cancer after local resection (complete en bloc resection with negative margins), have other cancers up to clinical stage T1a that can be judged to be cured by local treatment, registration is possible only if it is confirmed that the cancer was radically resected by local treatment. (2\) Active double cancer. (3\) In case of enrolled in Cohort A or Cohort D, history of surgery, chemotherapy, immunotherapy, or radiotherapy within 6 months before enrollment. (4\) Pregnant or breastfeeding women. (5\) Serious complication. (6\) Positive for HBs antigen or positive for HCV antibody\*. \*Patients who are positive for HCV antibody but negative for HCV\-RNA is eligible. (7\) HIV antibody positive (a patient may enroll even if HIV antibody has not been tested). (8\) Active novel coronavirus infection (COVID\-19\) is present\*. \* Patients with positive SARS\-CoV\-2 PCR or suspected COVID\-19 based on clinical symptoms; patients with confirmed negative SARS\-CoV\-2 PCR or other tests and no symptoms of COVID\-19 may be include in this study. However, if the physician deem that the patients will affect the evaluation of this study, the patients are ineligible. (COVID\-19 testing is not required). (9\) The study doctor deemed that it is ineligible for this study.